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Purpose: As part of the Danish Diabetes Impact Study 2013, we present trends in the inci-
dence, morbidity, mortality, and prevalence of diabetes in Denmark for the period 2000 through 
2011.
Patients and methods: The Danish National Diabetes Register was established in 2006 
and is assumed to cover all patients with diabetes, alive as of the end of 1996, and all subse-
quent new cases. The present study is based on the content of the register as of July 3, 2013 
(n=497,232 patients). Using the personal identification code assigned to all Danish inhabitants, all 
available supplementary information from the Danish National Patient Register and the Danish 
Civil Registration Service was used to define the date of diagnosis of diabetes and the first date 
of experiencing complications (grouped according to impact and severity).
Results: During the period of 2000 to 2011, the incidence rate of diabetes increased approxi-
mately 5% annually. During the same period, decreasing trends were observed for both the rates 
of progression in complications and of the complication-specific mortality. During the same 
period, the prevalence of diabetes doubled.
Conclusion: The increasing prevalence of diabetes in Denmark is driven by increasing incidence 
combined with decreasing morbidity and mortality in the population of patients with diabetes. 
These mechanisms will be explored further as part of the Diabetes Impact Study 2013, together 
with investigations into the socioeconomic and health economic aspects of diabetes.
Keywords: diabetes, registries, morbidity, complications
Introduction
Diabetes is a major global health problem, which currently affects millions of 
people worldwide with high and escalating costs to societies.1,2 We have established 
the Diabetes Impact Study 2013 with the aim to provide an updated account of the 
current and future epidemiological profile of diabetes in Denmark together with 
an appraisal of the costs to patients and society that is attributable to diabetes. 
The study takes advantage of the establishment of the Danish National Diabetes 
Register (NDR) in 20063 which, together with the high quality of Danish health 
registers, offers unique opportunities for epidemiological and public health research 
in diabetes.4
Here, we present the Diabetes Impact Study 2013 and the first epidemiological 
results, with focus on the trends in the incidence, the mortality, and the resulting 
prevalence of diabetes in Denmark from 2000 to 2011. As a novelty, we also introduce 
the framework of using register data to classify diabetes by complications status to 
investigate the epidemiological characteristics of chronic complications of diabetes.
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Patients and methods
Data sources
NDR is established on the basis of information contained 
in already existing Danish health registers,3 including the 
Danish National Patient Register (DNPaR),5 the Danish 
National Prescription Registry,6 and the Danish National 
Health Service Register.7 Linkage of person-specific data 
between the registers is possible using the personal identifi-
cation number that is assigned to each Danish citizen and is 
used for administrative purposes throughout the public and 
private sectors in Denmark. As previously summarized,3,8 
inclusion in NDR takes place for a given person when the 
first of several possible ascertainment criteria are met: the 
first date of either a contact registered in the DNPaR with a 
diagnosis relevant to diabetes mellitus, fulfillment of specific 
criteria of purchasing prescriptions with either insulin or 
peroral antidiabetic drugs, fulfillment of one of two specific 
patterns of measurement of blood sugar, or a registration of 
a chiropodist service specifically provided to a person with 
diabetes.
All data on moves, migrations, and deaths recorded 
for the population of NDR registrants were obtained from 
the Danish Civil Registration System, which, since 1968, 
has kept electronic records on all demographic data for all 
Danish inhabitants.9
NDR is supposed to cover all persons fulfilling inclusion 
criteria and being alive at the end of 1996 plus all persons 
with inclusion date since the start of 1997.
For the present analysis, a data set was extracted with all 
patients cumulatively registered with NDR on July 3, 2013 
(n=497,232). For these patients, all contacts (regardless of the 
date of contact) in DNPaR were extracted, including coded 
data in all diagnostic and therapeutic interventions performed, 
together with information on primary and secondary diagno-
ses underlying the contact, the hospital, and all relevant dates 
related to the contact. DNPaR contains information on all 
activities in the Danish hospitals back to 1977 for inpatient 
contacts and 1995 for outpatient contacts, including visits 
to emergency rooms.5
Establishing milestones in the 
lifetime cause of diabetes
By means of the personal identification number, data for 
each of the registrants in NDR were linked with DNPaR to 
establish relevant clinical milestones for each patient. These 
milestones included the date of first occurrence of the diag-
nosis of diabetes, and the date of first occurrence of codes 
classifying for chronic complications related to diabetes 
(see “Establishing the diagnosis of diabetes” section). 
Information from Danish Civil Registration System was 
used to establish the date of death (regardless of the cause 
of death) and the date of emigration as relevant.
Establishing the diagnosis of 
diabetes
The date of the clinical diagnosis of diabetes is not available 
in NDR and has been operationally established as the first 
date of fulfillment of a criterion for inclusion in NDR.8 If 
the first registration of a diagnosis or an intervention code 
specific for diabetes occurred in DNPaR for a patient before 
the date of inclusion registered with NDR, this date has been 
used as a proxy for the date of diagnosis. Otherwise, the date 
of inclusion in NDR has been used. The right column of 
Table 1 shows how groups of codes of diagnoses and inter-
ventions have been used in this process. The complete list of 
all the codes of diagnoses and interventions which qualify 
for the diagnosis of diabetes and related complications may 
be accessed from http://www.appliedeconomics.dk/index.
php/publications/reports-for-download.
Occurrence and classification of 
complications relevant for diabetes
We have attempted to assess when a patient has developed 
chronic diabetes complications based on coded information 
from the DNPaR. In the absence of published guidelines, we 
have relied on consultations with clinical experts combined 
with decisions made on the basis of the actual distribution 
of relevant codes. This classification scheme comprises three 
complication groups on a tentative basis: without evidence 
of complications from available data (complication group 0, 
CG0); with evidence of at least one complication of interme-
diate impact (complication group 1, CG1); and with evidence 
of at least one complication of major impact (complication 
group 2, CG2). We have assumed irreversibility so that once 
qualified for CG1, the patient cannot revert to CG0 and can 
only remain in CG1 until death or progression to CG2. For 
patients with transition directly from CG0 to CG2, it has 
been assumed, for computational reasons, that the patient first 
progresses to CG1, but instantaneously progresses further to 
CG2 without producing person-time in CG1.
The date of progression to a given complication group has 
been taken as the first occurrence of a code of diagnosis or 
procedure registered in DNPaR qualifying for a CG. Table 1 
(middle column) provides a summary of this information and 
the complete list of all the codes of diagnoses and interven-
tions, which qualify for a complication group and may be 
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accessed from http://www.appliedeconomics.dk/index.php/
publications/reports-for-download. Codes not qualifying for 
any complication are assigned to CG0 by default.
Some codes of diagnoses and procedures are specific for 
diabetes (eg, diabetic retinopathy), while others are unspecific 
(eg, myocardial infarction and amputations). For patients having 
developed such complication(s) before the operational date of 
the diagnosis of diabetes, the patients will be assigned to the 
Table 1 grouping of diagnoses and interventions used for classifying hospital activities by complication groups of relevance for 
diabetes and with respect to diagnostic specificity for diabetes
Diagnosis or procedure Qualifying for complication groupa Specificity for diabetesb
Diabetes in pregnancy, childbirth, and the puerperium 0 1
Diabetes, without indication of chronic complication 0 1
Hypoglycemic coma not otherwise specified 0 0
screening for diabetic retinopathy 0 1
Drug treatment or instruction specific for diabetes 0 1
acute myocardial infarction 1 0
Diabetes with complication, not further specified 1 1
Diabetes with complications in peripheral vascular system 1 1
Diabetes with eye complication 1 1
Diabetes with foot ulcer 1 1
Diabetes with microangiopathy 1 1
Diabetes with neurological complication 1 1
Diabetes with peripheral angiopathy 1 1
Diabetes with renal complication 1 1
Diabetic cataract 1 1
Diabetic polyneuropathy 1 1
Diabetic retinopathy not otherwise specified 1 1
Diseases of the lens 1 0
Polyneuropathy 1 0
Proliferative diabetic retinopathy 1 1
Uremia 1 0
simplex diabetic retinopathy 1 1
Cataract, retinopathy in diabetes 1 1
Diabetic angiopathy in extremities 1 1
Diabetic nephropathy, Kimmelstiel–Wilson syndrome 1 1
neuropathy, diabetic polyneuritis, diabetes 1 1
amputation at or below ankle level 1 0
Coronary bypass operation 1 0
surgery for eye complication 1 0
Treatment of ulcer of lower limb 1 0
Diabetes with gangrene; diabetic gangrene 2 1
Diabetes with multiple complications 2 1
Diabetic maculopathy 2 1
Dialysis 2 0
Diseases of the retina 2 0
heart failure 2 0
Kidney transplantation 2 0
renal failure 2 0
stroke 2 0
Blindness 2 0
gangrene of lower limb 2 0
intracerebral hemorrhage 2 0
amputation above ankle level 2 0
Notes: a0, complication group 0 (no signs of complications); 1, complication group 1 (complications of moderate impact); 2, complication group 2 (complications of major 
impact); bvalues indicate specificity for diabetes (0, unspecific for diabetes; 1, specific for diabetes).
concerned CG at the date of diagnosis of diabetes and the patient 
can only contribute with person-time at risk for progression to 
a more advanced CG.
Framework of epidemiological 
analysis
The epidemiological analyses of transition rates and 
prevalence proportions have been performed within 
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the framework of an illness-stage-death model outline 
in Figure 1. The number of persons present in each of the 
stages, represented in the flow chart in Figure 1, on the last 
date of a given calendar year represents the prevalence of 
patients with the complication status for that year. These 
numbers provide for the annual complication-specific 
prevalence proportions by division with the total population 
size. Annual transition rates (incidence rate of the disease; 
morbidity rates reflecting rates of progression from CG0 
to CG1 and from CG1 to CG2, respectively; and mortal-
ity rates from each of the complication groups) have been 
estimated from the numbers of transitions divided with 
the appropriate numbers of person-years at risk during the 
calendar year concerned.
For each calendar year, we calculated individual person-
time, in terms of 1) the exact number of days experienced in 
any combination of 5-year age-groups; and 2) complication 
status based on the transition dates between age-groups and 
complication groups. Age groups were further collapsed to 
the groups: 0–24, 25–49, 50–74, and 75+ years. The analyses 
of morbidity and mortality were done on the basis of age 
standardization within each sex using the age composition 
of the population of persons with diabetes 2006 ultimo.
For the estimation of the incidence rate of diabetes, popula-
tion time at risk of developing diabetes for each calendar year 
was obtained from Statistics Denmark,10 with subtraction of 
the person-time experienced with diabetes during that year in 
order to estimate true person-time at risk in the denominator. 
The analysis of incidence rate of diabetes was done on the 
basis of age standardization within each sex, using the age 
composition of the Danish population 2006 ultimo in four 
groups: 0–24, 25–49, 50–74, and 75+ years.10
c2-based analyses were employed to test for heterogeneity 
over calendar time. An approximated Poisson distribution 
and the binomial distribution for rates and proportions were 
used to calculate 95% confidence intervals.
Because we consider the first operational years of the 
NDR (1997–1999) as a running-in phase, the present analysis 
focuses on the period from 2000 to 2011.
Ethical aspects
The Diabetes Impact Study 2013 is an observational register-
based investigation with no contact to registered persons. 
Permission to extract and analyze data was obtained from the 
Danish Data Protection Agency (Jnr 2013-21-1749) and the 
Danish National Board of Health (FSEID-00000440).
Results
As of July 3, 2013, a total of 497,232 persons were registered 
in NDR. After exclusion of 688 persons with invalid or incon-
sistent data, 496,514 persons (99.9% of all registrants) were 
included in the present analysis.8 Table 2 contains a summary 
of all events observed and inferred from the registry data by 
complication group for the total population, with stratifica-
tion for men and women.
Incidence
The trend in standardized incidence rate is shown in Figure 2, 
demonstrating an increasing incidence, with fluctuations. 
There is strong evidence of heterogeneity between 
Population without registered diabetes 
Incidence
Morbidity Mortality 
Prevalence, complications
of major impact 
Prevalence, no
complications 
Prevalence, complications
of intermediate impact
Figure 1 an illness-stage–death model with three categories of complications as the framework for epidemiological analysis.
Notes: The model is populated on an annual basis. Numbers in the boxes represent annual complication-specific prevalence and numbers assigned to the arrows represent 
annual incidence, progression between complication categories (morbidity), and complication-specific mortality.
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calendar years (P,0.001). In absolute numbers, the incidence 
increased from approximately 18,000 new cases in year 
2000 to almost 32,000 new cases in year 2011, correspond-
ing to an average annual increase at approximately 5%. The 
men:women standardized rate ratio over the period was 1.25 
(P,0.001). Approximately 75% of the persons with diabetes, 
slightly higher for women than for men, were without com-
plications at diagnosis, and this proportion remained largely 
constant through the period of analysis (Table 2).
Complications
An increasing number of persons progressed to CG1 and 
CG2, respectively (Table 2), over the period. However, when 
taking into consideration the person-time at risk of develop-
ing these complications, the rate of developing complications 
decreased for both complication groups (Figure 3), mostly 
pronounced for the category of severe complications (CG2). 
These trends were statistically significant for men as well 
as for women (P,0.001). The rate of progression to CG1 
Table 2 summary of data by complication group
Year New cases of diabetes by  
complication status at diagnosis
Progressions to  
CG1 and CG2
Prevalent cases ultimo year by 
complication status
Number of deaths by 
complication status
CG0 CG1 CG2 Total CG1 CG2 CG0 CG1 CG2 Total CG0 CG1 CG2 Total
All
1999 na na na na na na 82,261 27,061 32,143 141,465 na na na na
2000 13,806 1,825 2,745 18,376 6,963 5,467 86,830 28,988 35,564 151,382 2,170 1,370 4,774 8,314
2001 14,727 2,020 2,913 19,660 7,122 5,644 92,131 31,111 39,088 162,330 2,193 1,341 4,998 8,532
2002 16,274 2,189 3,355 21,818 7,666 5,912 98,299 33,582 42,961 174,842 2,315 1,422 5,369 9,106
2003 17,696 2,432 3,644 23,772 8,246 5,910 105,273 36,806 46,836 188,915 2,310 1,512 5,653 9,475
2004 17,652 2,388 3,872 23,912 8,380 6,127 112,044 39,952 51,103 203,099 2,344 1,453 5,702 9,499
2005 16,206 2,343 3,588 22,137 8,305 6,053 117,467 43,012 54,627 215,106 2,333 1,479 6,097 9,909
2006 16,718 2,442 3,829 22,989 8,340 6,051 123,201 46,064 58,304 227,569 2,469 1,638 6,173 10,280
2007 17,967 2,411 4,040 24,418 7,651 5,727 130,841 48,661 61,667 241,169 2,533 1,686 6,375 10,594
2008 19,585 2,720 4,345 26,650 7,852 6,039 139,896 51,472 65,478 256,846 2,530 1,672 6,547 10,749
2009 19,580 2,641 4,367 26,588 8,252 6,386 148,353 54,108 69,233 271,694 2,732 1,808 6,963 11,503
2010 20,258 2,762 4,487 27,507 8,170 6,339 157,413 56,790 72,891 287,094 2,851 1,851 7,129 11,831
2011 23,622 3,107 5,092 31,821 8,343 6,523 169,635 59,813 77,176 306,624 2,823 1,841 7,237 11,901
Men
1999 na na na na na na 38,993 15,161 17,385 71,539 na na na na
2000 6,919 1,128 1,509 9,556 3,689 2,935 41,083 16,313 19,320 76,716 1,087 721 2,496 4,304
2001 7,357 1,232 1,613 10,202 3,869 3,058 43,432 17,628 21,344 82,404 1,070 712 2,621 4,403
2002 7,849 1,368 1,871 11,088 4,071 3,211 46,008 19,063 23,504 88,575 1,140 755 2,903 4,798
2003 8,838 1,524 2,035 12,397 4,470 3,277 49,126 20,969 25,781 95,876 1,143 788 3,020 4,951
2004 8,777 1,513 2,159 12,449 4,484 3,340 52,152 22,806 28,186 103,144 1,170 799 3,073 5,042
2005 8,094 1,451 2,032 11,577 4,442 3,396 54,613 24,463 30,340 109,416 1,105 807 3,256 5,168
2006 8,295 1,588 2,196 12,079 4,474 3,344 57,176 26,240 32,609 116,025 1,167 922 3,252 5,341
2007 8,898 1,536 2,249 12,683 4,080 3,187 60,674 27,738 34,605 123,017 1,229 897 3,418 5,544
2008 9,682 1,806 2,522 14,010 4,196 3,315 64,827 29,473 36,910 131,210 1,235 916 3,519 5,670
2009 9,988 1,713 2,581 14,282 4,562 3,595 68,829 31,113 39,222 139,164 1,349 991 3,846 6,186
2010 10,324 1,803 2,682 14,809 4,372 3,572 73,267 32,702 41,611 147,580 1,402 969 3,835 6,206
2011 11,786 2,000 3,031 16,817 4,525 3,655 79,015 34,535 44,220 157,770 1,388 1,012 4,023 6,423
Women
1999 na na na na na na 43,268 11,900 14,758 69,926 na na na na
2000 6,887 697 1,236 8,820 3,274 2,532 45,747 12,675 16,244 74,666 1,083 649 2,278 4,010
2001 7,370 788 1,300 9,458 3,253 2,586 48,699 13,483 17,744 79,926 1,123 629 2,377 4,129
2002 8,425 821 1,484 10,730 3,595 2,701 52,291 14,519 19,457 86,267 1,175 667 2,466 4,308
2003 8,858 908 1,609 11,375 3,776 2,633 56,147 15,837 21,055 93,039 1,167 724 2,633 4,524
2004 8,875 875 1,713 11,463 3,896 2,787 59,892 17,146 22,917 99,955 1,174 654 2,629 4,457
2005 8,112 892 1,556 10,560 3,863 2,657 62,854 18,549 24,287 105,690 1,228 672 2,841 4,741
2006 8,423 854 1,633 10,910 3,866 2,707 66,025 19,824 25,695 111,544 1,302 716 2,921 4,939
2007 9,069 875 1,791 11,735 3,571 2,540 70,167 20,923 27,062 118,152 1,304 789 2,957 5,050
2008 9,903 914 1,823 12,640 3,656 2,724 75,069 21,999 28,568 125,636 1,295 756 3,028 5,079
2009 9,592 928 1,786 12,306 3,690 2,791 79,524 22,995 30,011 132,530 1,383 817 3,117 5,317
2010 9,934 959 1,805 12,698 3,798 2,767 84,146 24,088 31,280 139,514 1,449 882 3,294 5,625
2011 11,836 1,107 2,061 15,004 3,818 2,868 90,620 25,278 32,956 148,854 1,435 829 3,214 5,478
Abbreviations: Cg0, no complications; Cg1, minor complications; Cg2, major complications; na, not available.
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was higher for men than for women, with a men:women 
standardized rate ratio at 1.37 (P,0.001), whereas the rate 
of progression to CG2 was more similar, yet statistically 
significantly different, for men and women with men:women 
standardized rate ratio at 1.03 (P,0.001).
Mortality
The number of deaths (regardless of cause of death) increased 
slightly from approximately 8,300 in year 2000 to almost 
12,000 in year 2011 (Table 1). However, when taking into 
consideration the person-time at risk of dying in the various 
complication groups, the mortality rate decreased for both men 
and women and for all complication groups (Figure 4). Overall, 
the standardized mortality rate declined from 5.7 deaths per 
100 person-years to 3.9 deaths per 100 person-years, cor-
responding with a decrease of 3% annually. The men:women 
standardized rate ratio was 1.29 (P,0.001). The mortality 
rate was lowest for CG0, with a decline in the rate from 2.9 
to 2.0 deaths per 100 person-years (men:women standardized 
rate ratio: 1.27, P,0.001). The mortality rate was intermedi-
ate for CG1, with a decline in the mortality rate from 5.1 to 
3.3 deaths per 100 person-years (men:women standardized 
rate ratio: 1.09, P,0.001). The mortality rate was highest 
for CG2, with a decline in the mortality rate from 11.4 to 7.4 
deaths per 100 person-years (men:women standardized rate 
ratio: 1.15, P,0.001).
Prevalence
The number of prevalent patients increased from approxi-
mately 140,000 patients at the end of the year 1999 to more 
than 300,000 at the end of the year 2011 (Table 2). The stand-
ard ized prevalence proportion increased from 28 per 1,000 
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population 1999 ultimo to 52 per 1,000 population 2011 ultimo 
(Figure 5). For each of the years covered by the study, men had a 
statistically significant (P,0.001) higher prevalence proportion 
than women, with the men:women standardized proportion ratio 
ranging from 1.1 to 1.4. The relative prevalence of patients in 
CG0 fell slightly from approximately 58% at the end of 1999 
to approximately 55% at the end of 2011 (Figure 6). This was 
caused by an increase in the proportion of patients in CG2 from 
less than 23% at the end of 1999 to more than 25% at the end of 
2011, whereas the proportion of patients in CG1 was almost 
constant throughout the period of analysis. As compared with 
women, there were relatively fewer men in CG0 and relatively 
more men in both CG1 and CG2 (data not shown).
Discussion
We have used already existing national health register data 
to establish a comprehensive characterization of the central 
epidemiological features of diabetes in Denmark, with all 
advantages and limitations attached to this approach.
Data from the nationwide Danish health registers are gen-
erally considered to have a very high level of completeness 
in terms of coverage of all the relevant persons and activi-
ties.4 Furthermore, using already existing data collected for 
purposes independent of the study concerned reduces both 
bias and need to collect additional data. Nevertheless, a series 
of limitations are involved when using NDR and the other 
Danish health registers for research purposes.8 Thus, NDR 
may include up to 20% registrants who do not have diabetes. 
A sensitivity analysis with exclusion of these persons yields a 
reduction of approximately 30% for all key figures presented 
in Table 1, but with similar trends in the proportions and rates 
as found for the total material.
Another concern is that for more than 10% of the reg-
istrants, the operationally established date of diagnosis of 
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diabetes is systematically biased toward too late a date.8 
We have addressed this issue by using the full information 
available in DNPaR to establish the earliest possible date of 
registration with a diabetes-specific event.
Relevant data on diabetes and comorbidity captured in 
the primary health care sector are not available in NDR and 
DNPaR, including values of glycosylated hemoglobin as 
well as measurements of microalbuminuria and results of 
screening for diabetes eye complications. Such information 
would improve the classification of diabetic complications 
by severity.
The data extracted from the DNPaR may suffer from 
misclassifications and errors in coding practice, and in addi-
tion, cause omissions of otherwise relevant registrations; 
such errors may lead to misclassification of the date of onset 
of complications. Compared with previous epidemiologi-
cal analyses based on NDR,11 our approach is novel as we 
attempted to assess complication status and categorize it by 
level of impact. Even though this may be questioned on clini-
cal grounds, it seems to work at the group level as evidenced 
by the fact that the mortality level is higher for the group of 
patients with complications of moderate impact as compared 
with patients without complications, but is even higher in the 
group of patients with complications of severe impact.
With these limitations in mind, we believe our results 
accurately reflect the current trends in diabetes epidemiology 
in Denmark and extend previous epidemiological analyses 
based on NDR by confirming an increasing incidence level.11 
Because the diagnosis of diabetes is established by means of 
the first occurrence of certain events, fluctuations in incidence 
occur as a consequence of changes in administrative practice, 
like reimbursement for services specific for patients with 
diabetes, but since the majority of patients are ascertained 
by hospital diagnoses or prescriptions with antidiabetic 
drugs, such explanation seems less likely.8 Alternatively, the 
increasing incidence level might be explained by increased 
awareness, leading to earlier diagnosis than in previous 
times. If so, it would be expected that the proportion of 
patients having signs of complications already at the time of 
diagnosis should decrease over time, but this is not the case, 
as evidenced in Table 2. Currently, no data are available to 
assess the impact of changes in overweight and obesity on 
the incidence rate of diabetes, thus making further investiga-
tions highly needed.
We find that the prevalence of diabetes is increasing expo-
nentially as evidenced by the net influx to the population of 
patients with diabetes (ie, the difference between the annual 
number of new cases and the annual number of deaths), which 
is steadily increasing. Our study demonstrates that this trend 
is driven not only by an increasing incidence, but also by a 
decreasing trend in the risk of developing complications as 
well as a decreasing mortality level regardless of the presence 
of complications, but with most reduction among patients 
with severe complications. These trends have been observed 
also in subsets of patients attending the Steno Diabetes Center 
in Denmark and have been ascribed to intensified glycemic 
control in the patient population.12 In this perspective, the 
emerging so-called diabetes epidemic is partly a result of 
improved care. We believe that the trends seen in the Danish 
population may be generalized to other nations with similar 
socioeconomic characteristics.
Our results have demonstrated that for incidence, com-
plication, and mortality rates as well as prevalence propor-
tions, men have higher levels than do females. Concerning 
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incidence rates and prevalence proportions, this pattern was 
also observed from the first epidemiological analyses on the 
basis of NDR data,11 but so far these observations remain 
unexplained.
Together with our previously published study on the 
validation of the NDR,8 the results of the present study 
provide the basis of additional studies. As part of the 
Diabetes Impact Study 2013, we will perform in-depth 
analysis of the relative importance of those factors that 
drive the prevalence and use such models to establish 
scenarios for the future evolution of the prevalence of dia-
betes in Denmark, in line with similar approaches in other 
communities.13 New insight into the future societal burden 
of diabetes will be obtained by combining epidemiological 
data with information on patients’ demographic, ethnic, and 
socioeconomic characteristics as well as estimates of costs 
attributable to diabetes within categories characterized by 
age, sex, and complication status.
Conclusion
The prevalence of patients with diabetes registered in Denmark 
is rising exponentially due to the synergistic effect of increasing 
incidence combined with decreasing rate of developing compli-
cations as well as decreasing mortality in the patient population. 
Further studies will seek to quantify the relative importance of 
these factors, and this will enable for establishment of scenarios 
for estimating the future burden of diabetes.
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